文献速递神经肌肉病脑血管病

山梨醇是PMM2-CDG的严重程度生物标志物并具有治疗意义

Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
PubMed 文献 · Ann Neurol · 2021-10-26

本研究评估了PMM2-CDG患者的遗传、生化及临床特征,包括NPCRS评分、尿多元醇水平和成纤维细胞糖蛋白组学。在体外,依帕司他治疗可提高PMM酶活性并改善N-糖基化;一名患儿接受0.8 mg/kg/日口服依帕司他治疗12个月,共济失调评分和生长改善,尿山梨醇3个月内接近正常,转铁蛋白糖基化6个月正常。尿山梨醇在74%患者中升高,与周围神经病变和CDG严重程度评分相关。

要点

  • 尿山梨醇在74%的PMM2-CDG患者中升高,与周围神经病变和CDG严重程度评分相关。
  • 依帕司他在体外提高PMM酶活性并改善N-糖基化。
  • 一名患儿经依帕司他治疗12个月,共济失调和生长改善,尿山梨醇和转铁蛋白糖基化恢复正常。

核心结论

  • 依帕司他在体外改善PMM酶活性、N-糖基化和糖基化生物标志物。
  • 依帕司他在首例接受治疗的PMM2-CDG患儿中耐受良好并带来显著临床改善。
  • 尿山梨醇被提议作为PMM2-CDG疾病严重程度和治疗反应的新型生物标志物。

研究设计与样本

  • 在PMM2缺陷成纤维细胞中进行PMM酶测量、多重蛋白质组学和糖蛋白组学,比较依帕司他治疗前后。
  • 一名PMM2-CDG患儿接受0.8 mg/kg/日口服依帕司他治疗12个月,评估安全性和有效性。
  • 评估患者的遗传、生化及临床特征,包括NPCRS、尿多元醇水平和成纤维细胞糖蛋白组学。

主要发现

  • 依帕司他治疗后PMM酶活性增加。
  • 与对照相比,24%的糖肽在PMM2缺陷成纤维细胞中丰度降低,其中46%在治疗后改善。
  • 依帕司他治疗后总蛋白N-糖基化改善,整体糖基化向对照成纤维细胞谱靠近。
  • 74%的PMM2-CDG患者尿山梨醇水平升高,且与周围神经病变和CDG严重程度评分的存在相关。
  • 接受依帕司他治疗的患儿共济失调评分改善并伴有显著生长改善;尿山梨醇3个月内接近正常,血转铁蛋白糖基化6个月正常。

临床怎么用

  • 尿山梨醇可作为PMM2-CDG疾病严重程度和治疗反应的生物标志物用于未来临床试验。
  • 依帕司他可能改善PMM2-CDG患者的PMM酶活性、糖基化和临床结局。

局限性

  • 依帕司他的安全性和有效性仅在一名PMM2-CDG患儿中研究12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM) enzyme activity in a PMM2-congenital disorders of glycosylation (CDG) worm model. Epalrestat also decreases sorbitol level in diabetic neuropathy. We evaluated the genetic, biochemical, and clinical characteristics, including the Nijmegen Progression CDG Rating Scale (NPCRS), urine polyol levels and fibroblast glycoproteomics in patients with PMM2-CDG. METHODS: We performed PMM enzyme measurements, multiplexed proteomics, and glycoproteomics in PMM2-deficient fibroblasts before and after epalrestat treatment. Safety and efficacy of 0.8 mg/kg/day oral epalrestat were studied in a child with PMM2-CDG for 12 months. RESULTS: PMM enzyme activity increased post-epalrestat treatment. Compared with controls, 24% of glycopeptides had reduced abundance in PMM2-deficient fibroblasts, 46% of which improved upon treatment. Total protein N-glycosylation improved upon epalrestat treatment bringing overall glycosylation toward the control fibroblasts' glycosylation profile. Sorbitol levels were increased in the urine of 74% of patients with PMM2-CDG and correlated with the presence of peripheral neuropathy, and CDG severity rating scale. In the child with PMM2-CDG on epalrestat treatment, ataxia scores improved together with significant growth improvement. Urinary sorbitol levels nearly normalized in 3 months and blood transferrin glycosylation normalized in 6 months. INTERPRETATION: Epalrestat improved PMM enzyme activity, N-glycosylation, and glycosylation biomarkers in vitro. Leveraging cellular glycoproteome assessment, we provided a systems-level view of treatment efficacy and discovered potential novel biosignatures of therapy response. Epalrestat was well-tolerated and led to significant clinical improvements in the first pediatric patient with PMM2-CDG treated with epalrestat. We also propose urinary sorbitol as a novel biomarker for disease severity and treatment response in future clinical trials in PMM2-CDG. ANN NEUROL 20219999:n/a-n/a.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Ligezka AN, Radenkovic S, Saraswat M, et al. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications. Ann Neurol. 2021. PMID: 34652821. doi:10.1002/ana.26245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。